EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

DPYD c.85 T > C, DPYD c.496 A>G, and DPYD c.2194 G>A and severe toxicity to fluoropyrimidines in PREPARE and Alpe-DPD trials. An original study and meta-analysis

Elena De Mattia, Jerry Polesel, Maaike van der Lee, Stefan Bohringer, Martina Gambron, Samantha Perfler, Rossana Roncato, Giovanni Canil, Bianca Posocco, Annemieke Cats, Ron H J Mathijssen, Henk-Jan Guchelaar und 6 weitere

Pharmacological Research · 2026

DOI: 10.1016/j.phrs.2026.108451 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Pharmacological Research, 2026. Verfasst von Elena De Mattia und 17 weiteren Autor:innen. Beteiligte Einrichtung: Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, via Franco Gallini n. 2, Aviano, PN, 33081, Italy. Hauptthemen laut MEDLINE: Dihydrouracil Dehydrogenase (NADP), Antimetabolites, Antineoplastic. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministero della Salute, KWF Kankerbestrijding, Horizon 2020 Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current DPYD genotyping panels used to prevent fluoropyrimidine (FL)-related toxicity explain only a limited proportion of severe adverse events. The clinical relevance, beyond current testing, of additional DPYD variants, including DPYD*6 (c.2194 G>A, rs1801160), DPYD c.496 A>G (rs2297595), and DPYD*9 A (c.85 T > C, rs1801265) remains debated. This study evaluated each polymorphism individually, irrespective of the allelic configuration at the other investigated loci, and as part of three-locus haplotypes in relation to severe FL-related toxicity. For single-variant effects, data from patients enrolled in two trials (PREPARE, Italian cohort; Alpe-DPD) were combined with 31 eligible published studies in a meta-analysis comprising 33 studies and 17,485 patients, with subgroup analyses by ethnicity. Haplotype analyses were performed in the 1296 trial participants. LC-MS was applied to evaluate plasma uracil and dihydrouracil levels. In the meta-analysis, DPYD c.2194 G>A (OR=1.70; 95%CI: 1.48-1.95) and c.496 A>G (OR=1.55; 95%CI: 1.19-2.02) were associated with FL toxicity. No overall association was observed for c.85 T > C; however, it improved c.496 A>G associated risk prediction in a haplotype analysis. Haplotype #3 (minor c.496 G with major c.85 T) was consistently associated with increased severe overall toxicity (PREPARE: OR=2.62, 95%CI: 1.06-6.50; Alpe-DPD: OR=2.09, 95%CI: 1.01-4.37) and gastrointestinal toxicity (PREPARE: OR=5.65, 95%CI: 2.11-15.15; Alpe-DPD: OR=2.71, 95%CI: 1.23-5.97). An exploratory Receiver Operating Characteristic (ROC) curve analysis demonstrated a significant incremental gain in risk discrimination achieved by adding DPYD c.85 T > C to a model that already included c.496 A>G. Haplotype #4 (minor alleles at both loci) was not associated with toxicity, suggesting a functional interaction between the variants. DPYD c.2194 G>A did not add to haplotype-based stratification. In PREPARE, pre-treatment plasma uracil and dihydrouracil confirmed reduced DPD function in haplotype #3 carriers. Overall, DPYD c.2194 G>A and c.496 A>G increased severe FL-toxicity risk when evaluated individually, whereas the integration of c.85 T > C refined risk prediction in a haplotype-based approach, supporting further refinement of pharmacogenetic risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydrouracil Dehydrogenase (NADP)Antimetabolites, AntineoplasticHumansPolymorphism, Single NucleotideHaplotypesUracil

Stichwörter der Autor:innen

DPYDDPYD c.2194 G>ADPYD c.496 A>GDPYD c.85 T > CFluoropyrimidinesHaplotypeMeta-analysisToxicity

Substanzen

Dihydrouracil Dehydrogenase (NADP)UracilAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, via Franco Gallini n. 2, Aviano, PN, 33081, Italy.
  • Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, via Franco Gallini n. 2, Aviano, PN, 33081, Italy.
  • Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2300 RC, the Netherlands.
  • Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, via Franco Gallini n. 2, Aviano, PN, 33081, Italy; Department of Medicine, University of Udine, via Colugna 50, Udine, 3310…
  • Department of Gastrointestinal Oncology, Division of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, 1066 CX, the Netherlands.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Centre, Dr Molewaterplein 40, Rotterdam, 3015 CN, the Netherlands.

Förderung

  • Ministero della Salute
  • KWF Kankerbestrijding
  • Horizon 2020 Framework Programme
  • Horizon 2020

Zitieren

APA

De Mattia, E., Polesel, J., van der Lee, M., Bohringer, S., Gambron, M., Perfler, S., Roncato, R., Canil, G., Posocco, B., Cats, A., Mathijssen, R. H. J., Guchelaar, H. J., Schellens, J. H. M., Gelderblom, H., Spina, M., Puglisi, F., Swen, J. J., & Cecchin, E. (2026). DPYD c.85 T > C, DPYD c.496 A>G, and DPYD c.2194 G>A and severe toxicity to fluoropyrimidines in PREPARE and Alpe-DPD trials. An original study and meta-analysis. Pharmacological Research. https://doi.org/10.1016/j.phrs.2026.108451

Vancouver

De Mattia E, Polesel J, van der Lee M, Bohringer S, Gambron M, Perfler S, et al. DPYD c.85 T > C, DPYD c.496 A>G, and DPYD c.2194 G>A and severe toxicity to fluoropyrimidines in PREPARE and Alpe-DPD trials. An original study and meta-analysis. Pharmacological Research. 2026. doi:10.1016/j.phrs.2026.108451

BibTeX
@article{DeMattia2026,
  author = {De Mattia, Elena and Polesel, Jerry and van der Lee, Maaike and Bohringer, Stefan and Gambron, Martina and Perfler, Samantha and Roncato, Rossana and Canil, Giovanni and Posocco, Bianca and Cats, Annemieke and Mathijssen, Ron H J and Guchelaar, Henk-Jan and Schellens, Jan H M and Gelderblom, Hans and Spina, Michele and Puglisi, Fabio and Swen, Jesse J and Cecchin, Erika},
  title = {DPYD c.85 T > C, DPYD c.496 A>G, and DPYD c.2194 G>A and severe toxicity to fluoropyrimidines in PREPARE and Alpe-DPD trials. An original study and meta-analysis},
  journal = {Pharmacological Research},
  year = {2026},
  doi = {10.1016/j.phrs.2026.108451}
}
Kostenlos starten →